Athenex to Present at the 17th Annual Needham Healthcare Conference
March 27 2018 - 8:00AM
Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced Dr. Simon Pedder, Chief Business and Strategy
Officer, will present at the 17th Annual Needham Healthcare
Conference in New York City on Tuesday, March 27, 2018 at 2:00 pm
EDT.
The presentation will be webcasted, and can be accessed at the
Investor Relations section of the Company’s website, located at
www.athenex.com. An archive will be available on this website until
April 27, 2018.
About Athenex, Inc.Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery and development of next generation drugs for the
treatment of cancer. Athenex is organized around three
platforms, including an Oncology Innovation Platform, a Commercial
Platform and a Global Supply Chain Platform. Athenex’s Oncology
Innovation Platform generates clinical candidates through an
extensive understanding of kinases, including novel binding sites
and human absorption biology, as well as through the application of
Athenex’s proprietary research and selection processes in the lab.
The Company’s current clinical pipeline is derived from two
different platform technologies Athenex calls Orascovery
and Src Kinase Inhibition. The Orascovery platform is based on the
novel oral P-glycoprotein pump inhibitor molecule HM30181A, through
which Athenex is able to facilitate oral absorption of
traditional cytotoxics, which Athenex believes may offer
improved patient tolerability and efficacy as compared to IV
administration of the same cytotoxics. The Orascovery platform was
developed by Hanmi Pharmaceuticals and licensed
exclusively to Athenex for all major worldwide
territories except Korea, which is retained by Hanmi. The Src
Kinase Inhibition platform refers to novel small molecule compounds
that have multiple mechanisms of action, including the inhibition
of the activity of Src Kinase and the inhibition of tubulin
polymerization during cell division. Athenex believes the
combination of these mechanisms of action provides a broader range
of anti-cancer activity as compared to either mechanism of action
alone. Athenex’s employees worldwide are dedicated to improving the
lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan and multiple locations
in Chongqing, China.
CONTACT:Jim PolsonTel: +1-716-427-2952Athenex, Inc.
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Sep 2023 to Sep 2024